CANNOT BUY ONLINE

Sudden take off with no apparent news??

More good news contract win with Rene,
Biopharmaceutical contract manufacturer Angel Biotechnology Holdings has signed a GMP manufacturing contract with ReNeuron Group plc.

The signing of this contract follows on from ReNeuron's recent MHRA regulatory approval to commence a clinical trial with stem cell therapy for stroke.

As ReNeuron's manufacturing partner, Angel will be manufacturing the stem cell clinical product for a phase one clinical trial.

The value of the contract was not disclosed.

18 January 2010

Angel Biotechnology Holdings Plc ("Angel" or the "Company")
Trading Update

Angel Biotechnology Holdings Plc, (AIM: ABH) the biopharmaceutical contract manufacturer, is pleased to provide an update on trading activities for the six month period ended 31st December 2009

Business Highlights during the period include:

8 new contracts with a total value in excess of 2.2m were secured in H2. In addition, the Frame Agreement signed with Materia Medica represents a new opportunity for non-manufacturing contracts and a simpler mechanism for signing this business.

The value of contracts signed in the full year 2009 exceeds 3.8m. A significant part of the related revenues will be recognised over the 2010 and 2011 financial years.

We expect to announce a substantial increase in revenues in full year 2009 over full year 2008.

We have already signed more than 67% of our budgeted business for 2010 and we have a pipeline of potential new business with an estimated value of more than 6m.

Involvement in 3 grant awards in the cell therapy and regenerative medicine fields.

Gordon Sherriff, COO of Angel Biotechnology Holdings Plc, said: "Angel has enjoyed a productive and successful second half 2009. Based upon the amount of business already signed up for 2010 and our continued business development efforts, we expect 2010 to be a strong year. We are also seeing demand for stand alone regulatory services and intend to develop this aspect of our business. As a result of the strong demand for our core cGMP manufacturing services, we are now actively assessing options to expand our existing capacity and the means by which this can be achieved most expeditiously. This will include construction of new cGMP production space."

Making me a nice profit so far.

Bought in this morning @ .00494p ... probably bought at the top of the spike and it'll fall now...apologies if it does!...however, med/long term good story developing here so will hold for a good while.... onwards and upwards!

nice to see you here and yes you've sent it down, lol not sure if it will continue to rise as much as last time. BB

As ever, my first purchase was bought a couple of weeks ago at the top of the spike!

So...bought some more this morning to average out....must be onto a winner at these levels ?

thought at the time you got in high, I didn't get out on the peak but still got nice profit, as you say back to normal now and wait for next news.

The more you read the recent announcements the more convinced I am that there are significant gains to be made from these levels as ABH moves into profitability, so will buy more when I have some funds freed up... the next set of results (prob due end Mar/April) should make good reading....(imho)...onwards and upwards!

Am back in at .26p a few days ago and waiting for news.

"back in"

:-))

after all the sh*t you gave me a day ago........

no wonder it's gone to 25p

Balderboy.

Stop being abusive, you were encouraging me to buy Abh last week and then you post you have "bought back in" suggesting that you sold very quickly after your
post last week, not really what you would class as reliable, better off sticking to
the other side, they all seem to post like that :-))

Just too much stock floating about for me to get involved, i've saved 15% by sticking to that theory from last week.

Pot calling kettle black when it comes to abuse i think, can't help if you assume the wrong meaning, IF you had looked at the chart as suggested the last spike was a few days ago, I had bought at .27p and sold on spike at .49p and now back in at 26p and waiting. Profit whether YOU like it or not....

Ok you have it your way, i will filter you out and ignore you from now on.

Good luck

lovely.

Rec'd this earlier tonight...nothing new and you might've already seen this...


Buy Angel Biotechnology (ABH) at 0.24p

Says The AIM & PLUS Newsletter

THE BUSINESS

Penny stock Angel Biotechnology joined AIM in november 2005 raising GBP1.5 million to pursue its ambition of becoming a leading manufacturer of biopharmaceuticals. founded in December 2000 the Edinburgh-based business manufactures and supplies biologics (medicines produced through biological processes rather than combining chemicals) to biotechnology and pharmaceutical firms. some of the applications of its expertise include treatments for hospital acquired infections such as Mrsa and Clostridium difficile (C-Diff), virus-based treatments for cancer tumours and new stem cell-based treatments. the company specialises in early stage drug development work, on behalf of clients, for pre-clinical studies and Phase i, ii and iii of clinical trials.

Angel derives its competitive advantage through two important licences. these authorisations enable the firm to manufacture investigational medicinal products for the purpose of trials and to manufacture licensed products. the licences are subject to audits every two years by the government's medicine safety regulator: the Medicines and Healthcare Products regulatory agency (MHRA). in addition, the company's Pentlands science Park facility is licensed by the Human tissue authority thus enabling the storage, use and disposal of human tissue in the UK.

So why do companies use Angel Biotechnology's services? not only do they enable firms to comply with CGMP (current good manufacturing practice regulations) in drug development, which require those involved in the industry to ensure the safety and efficacy of drugs, clients can reduce the risk and costs involved with developing new medicines by outsourcing to Angel.

Contracts received by the business are typically longterm in nature, with revenue recognition triggered by the achievement of certain milestones. revenues are reported on a geographical basis and in the 2008 financial year sales from the UK accounted for 75.6% of group turnover. operations in the rest of Europe accounted for 19.8% of revenues, while business from the USA and Canada and the rest of the World made up the remainder.




FINANCIALS

In results for the six months to 30th June 2009 the firm reported a 25% increase in sales, to GBP600,000, despite reporting that manufacturing companies had scaled back their research spending as they opted to conserve cash during the downturn. However, a 66% increase in cost of sales to GBP422,000 coupled with a 6% rise in operating expenses to GBP670,000 as the firm expanded operations to deliver new programmes resulted in an 11.7% widening in pre-tax losses to GBP516,000. Losses per share remained unchanged at 0.04p as the exercise of warrants expanded the number of shares in issue.

At the half-year end the' balance sheet presented a not so pleasing picture, with net current liabilities of GBP1.78 million and net liabilities of GBP1.4 million as a result of GBP6.4 million in historic losses. During the first six months of 2009 just GBP28,000 in cash was generated from operations, which after deducting interest payments and funds used for investment resulted in cash holdings rising by GBP10,000 on the year-end figure to GBP83,000. While this is a worrying position a number of developments seen since the half-year end should enable the Angel to continue to finance operations. in november 2009 the firm secured a GBP4 million committed equity facility with trafalgar Capital advisers under which it will be able to access funds through the placing of shares. since the half-year end liabilities to the company's stockbrocker and Trafalgar Capital advisers have been paid down by issuing shares on three occasions. In addition, further breathing room was gained whe n EPhag as, a major shareholder and client, agreed not to redeem its GBP383,000 loan note before June 2010 under revised terms.

On the outlook Angel said in its results that a "major proportion" of contracts from a russian customer will be recognised in the second half of the 2009 financial year and in the first six months of 2010. Encouragingly, the company reported its best-ever pipeline of work, with a number of new contracts at an advanced stage of negotiation together with quotations for a number of new projects with existing customers. the company added that it anticipated the trading climate to remain difficult but expressed optimism about its future in light of its ability to take on a wider variety of projects and the possibility of collaborating with other firms in order to develop new medicines

Click for Full Charting facilities from ShareCrazy.com


CURRENT TRADING

Since its half-year end the biotechnology specialist has announced a number of contract wins. a notable deal was the October 2009 signing of a fourth manufacturing contract with russian pharmaceutical firm Materia Medica, a long standing client, for approximately GBP1.2 million. 90% of the value of the deal will be recognised over the next one and a half years. another important contract, worth approximately GBP0.5 million, was secured in December 2009. the deal, due for completion in June 2010, involves the manufacture of an advanced biologic for Phase ii clinical trials on behalf of an unnamed UK-based biotechnology firm. another GBP110,000 deal with Materia Medica was signed in January 2009 for regulatory consultancy services. the total value of these long-term deals alone equates to GBP1.81 million in revenues, which is nearly twice sales achieved in the 2008 financial year.

In addition to the above contracts the firm has also secured new business with other clients for which financial details have not been disclosed. an agreement was struck with Azellon Ltd, a spin-out company from the University of Bristol, to work on Phase i studies of a cell therapy treatment for the repair of meniscal (crescent shaped muscular) tears. a minor deal to work as a contractor alongside three consortiums of UK companies involved in regenerative medicine has also been secured and a contract has been signed with AIM-listed stem cell therapy business Reneuron Group to perform work to further develop and manufacture clinical-grade lots of a second-generation formulation of Reneuron's CTX stem cell line, for subsequent pre-clinical and clinical applications.

But the most upbeat news came in the form of a trading update for the second half of the year to 31st December 2009. Angel said a "substantial increase" in year-on-year revenues would be announced in results for the 2009 financial year, while 67% of budgeted business had been secured for 2010. By the 2009 financial year the firm said contracts worth GBP3.8 million (four times 2008 revenues) had been signed, with a significant part of these sales due to be recognised in 2010 and 2011. Work is also ongoing to secure potential new business opportunities worth GBP6 million. Encouragingly, the firm also noted "strong demand" for its core manufacturing services and was considering expanding capacity. furthermore, it noted growing demand for the provision of standalone regulatory services, a new area of activity, and was looking to develop this new revenue stream.

OPPORTUNITIES & THREATS

The company feels that the drive by governments to reduce the costs of medicine, as well as the threat to the industry posed by generic drugs, mean that pharmaceutical firms will look towards biopharmaceuticals as a way to create a new range of patented products. in this regard Angel believes it is well-placed to take advantage of new opportunities opening up in the bacteria, advanced biologics and regenerative medicine markets.

Another opportunity comes from legislation that encourages the development of stem cell research. in March 2009 US President Barack Obama lifted a ban on federal funding of stem cell research in the US thereby encouraging research in this field. furthermore, in the UK, in May 2008 the UK government approved research using human-animal hybrid embryos. While this vote is part of a much larger Human fertilisation and Embryology Bill, any further legislation opening up research on these issues will also work to the firm's advantage.

A significant threat to the execution of Angel Biotechnology's strategy comes from possible cuts in research and development spend by its clients. an anaemic economic recovery would mean that firms would continue to be reluctant to invest in new treatments thus impacting Angel Biotechnology's business opportunities. furthermore, since the majority of the firm's turnover comes from the UK, its prospects are tied to the health of pharmaceutical industry and business optimism in the UK.

Another major problem facing the company is its weak balance sheet. While the equity facility agreed provides a source of funds, use of this means of funding will lead to investors being diluted. While the firm has secured a number of new contracts since the half-year end we note that there is a long lead time (between 6 and 12 months) before an opportunity is converted into a sale. furthermore anticipating future revenues is difficult, leading to variability in year-on-year revenues. this is because the company has long-term deals with clients with revenues recognised as and when milestones are reached.

VALUATION

Due to the firm's loss making nature and its weak funding position at the half-year end it is difficult to value Angel Biotechnology using conventional earnings and net-asset based metrics. in addition, there are no forecasts currently available on the market. DisclAIMers out of the way, the investment case rests on the spate of contract wins secured consortiums of UK companies involved in regenerative medicine has also been secured and a contract has been signed with AIM-listed stem cell therapy business Reneuron Group to perform work to further develop and manufacture clinical-grade lots of a second-generation formulation of reneuron's CtX stem cell line, for subsequent pre-clinical and clinical applications.

But the most upbeat news came in the form of a trading update for the second half of the year to 31st December 2009. Angel said a "substantial increase" in year-on-year revenues would be announced in results for the 2009 financial year, while 67% of budgeted business had been secured for 2010. By the 2009 financial year the firm said contracts worth GBP3.8 million (four times 2008 revenues) had been signed, with a significant part of these sales due to be recognised in 2010 and 2011. Work is also ongoing to secure potential new business opportunities worth GBP6 million. Encouragingly, the firm also noted "strong demand" for its core manufacturing services and was considering expanding capacity. furthermore, it noted growing demand for the provision of standalone regulatory services, a new area of activity, and was looking to develop this new revenue stream.

A significant threat to the execution of Angel Biotechnology's strategy comes from possible cuts in research and development spend by its clients. an anaemic economic recovery would mean that firms would continue to be reluctant to invest in new treatments thus impacting Angel Biotechnology's business opportunities. furthermore, since the majority of the firm's turnover comes from the UK, its prospects are tied to the health of pharmaceutical industry and business optimism in the UK.

Another major problem facing the company is its weak balance sheet. While the equity facility agreed provides a source of funds, use of this means of funding will lead to investors being diluted. While the firm has secured a number of new contracts since the half-year end we note that there is a long lead time (between 6 and 12 months) before an opportunity is converted into a sale. furthermore anticipating future revenues is difficult, leading to variability in year-on-year revenues. this is because the company has long-term deals with clients with revenues recognised as and when milestones are reached.

In the second half of 2009 and the potential revenue visibility on offer in light of the multi-year nature of the recent deals. Despite doubts over the funding situation and the scheduled repayment of its convertible loan we believe the shares are due a re-rating as revenues are recognised and cash flows in as contracts are delivered. SPECULATIVE BUY.

Key Data
EPIC: ABH
Market: AIM
Spread: .23p - .24p (4%)

Results released today look good to me for a company at this stage of thier development. good pipeline of contracts with more to be announced...one for the back burner for us LTHs but I've no doubt we'll be rewarded. Will buy more on any significant dips...

GL to all genuine LTH ABH believers!

Bought more this morning...it's looking good!

good for you, still have plenty myself.

How do you think the sp is going to play out?...I've seen on other boards people saying that there's too many shares in circualtion for the sp to strengthen significantly,if at all...

just waiting for more contract news, which they're picking up all the time. They could consolidate if things get good.

Looks like something stirring here, news immenent I reckon, been creeping up last couple of days.....hopefully another contract win.,.

'bout time too !...nice rise today as well!

This is coming good at last...good story unfolding here..I hope! (imho)

its in the news - BUYYYYYYYYYYYYYYYYYYYYYYYYYY! imo

spread the word...

http://www.bbc.co.uk/news/health-11763681

16 November 2010 Last updated at 09:55 GMT Share this pageFacebookTwitter ShareEmail Print Stem cells used in stroke trialBy Pallab Ghosh

Science correspondent, BBC News Trial patients will get progressively higher doses of stem cells Continue reading the main story
Related stories
Q&A: Stem cells
Stem cells repair stroke damage
Doctors in Glasgow have injected stem cells into the brain of a stroke patient in an effort to find a new treatment for the condition.

The elderly man is the first person in the world to receive this treatment - the start of a regulated trial at Southern General Hospital.

He was given very low doses over the weekend and has since been discharged - and his doctors say he is doing well.

Critics object as brain cells from foetuses were used to create the cells.

The patient received a very low dose of stem cells in an initial trial to assess the safety of the procedure.

Over the next year, up to 12 more patients will be given progressively higher doses - again primarily to assess safety - but doctors will be looking closely to see if the stem cells have begun to repair their brains and if their condition has improved.

Early stages

Continue reading the main story

Start Quote
We hope that in the future it will lead to larger studies
End Quote
Professor Keith Muir

Glasgow University
The company making the stem cells says the trial has ethical approval from the medicine's regulator.

It also points out that foetuses were used in the very early stages of the research and are now no longer used.

Professor Keith Muir, a neuroscientist at Glasgow University and a consultant neurologist at Southern General Hospital, said if the trials went well it would lead to more detailed research.

"We hope that in the future it will lead to larger studies to determine the effectiveness of stem cells on the disabilities that result from strokes," he said.

The first group of patients to receive the treatment will be men over 60 who have shown little or no improvement in their condition over a number of years.

It is an ideal group to assess the safety of the procedure - doctors will be keen to know first of all that the treatment makes them no worse.

But having such a precisely defined group will enable doctors and scientists to compare like with like if they notice any improvement - even in these early stages.

If these trials show promise, doctors plan larger trials on a more varied group of patients. The earliest this could begin is in two years' time.

There will be more focus on assessing the effectiveness, if any, of the stem cell treatment and on which groups it works best.

Patients will be monitored for two years, followed by longer term procedures after that.

Advertisement
Professor Anthony Rudd of St Thomas' Hospital explains what happens during and after a stroke

The announcement from the Glasgow team comes a few weeks after the US firm Geron said it had begun its clinical trials on a patient to develop a treatment for paralysis.

The development of stem cell treatments is still at a research stage and it is likely to be many years before becoming widely available.

But new potential treatments are now beginning to make their way from the scientist's laboratory into the doctor's clinic.

Strokes kill around 67,000 people in the UK every year, according to the Stroke Association.

The charity says it is the third most common cause of death in England and Wales after heart disease and cancer.

The disabilities suffered by patients also have a greater impact than any other chronic disease, it adds.

already in and waiting......fantastic news but maybe 2 years for results, lots of other things going on i'm sure to keep sp climbing.,.

It's moving up nicely ! Glad I stuck with this one...will continue to hold!

satisfactory day at the office - lol
hope you guys caught it in time if not already
kerrrrrrchinnnnnnnnnngggg!

reckon there will be somemore to come tomorrow morning.,.

me too - rns today out more good news!

kerrrchinnnnng +!

.82 is broker target before yesterday's news!! lol

Am out for now at 62, halifax buggered about when i wanted to sell at 68.....but 2.5 times my input is lovely. back in when the dust settles.,. ;))

gibby did you sell or hold??

Bought some more y'day at 33.....

From traderstreasure.com

Angel on your shoulder!
19/11/10 08:20 Filed in: Angel Biotechnology Hldgs
This rather small company cant quite produce fast enough for the customers out there! They are soon to re-open a mothballed facility which can only have a positive effect on the SP.
More of a long term hold on this one, although you will see some big jumps along the way!

So did I also at 33 mostly because Halifax had a free deal time midday so good value and extra shares with the 11.95.,. last time held at 24 sold at 61, nice profit now sit and wait for next spike. happy days.

feel another quick profit coming:

ANGEL BIOTECHNOLOGY HOLDINGS PLC

("Angel" or "the Company")



Angel and Materia Medica announce new GMP Manufacturing Contract



Angel Biotechnology Holdings plc, (AIM: ABH) the biopharmaceutical contract manufacturer, is pleased to announce the signing of a new GMP Manufacturing contract with Materia Medica Holdings, a leading pharmaceutical company in Russia. The contract for process development and GMP manufacture of specific antibodies is valued at circa 1.53 million. The GMP manufacture will complete in late 2012.

Commenting on the contract, Gordon Sherriff, Angel's Chief Operating Officer said: "We have been working with Materia Medica for over 3 years now and this is the 6th contract for the process development and GMP manufacturing of their innovative products. We are very pleased to have again found the technical solutions which Materia Medica requires for this latest project, and to be able to continue our commitment to working with Materia Medica by supporting the regulatory compliant manufacture of its pipeline of products. Supporting clients with advanced biologics through often complex regulatory hurdles is a significant part of Angel's service offering.

Sergey Tarasov, of Materia Medica Holding R&D department, said: "We are delighted to award a further GMP contract to Angel. This product is key to our product portfolio and Angel's continued ability to identify a regulatory compliant manufacturing route demonstrates the strong relationship our companies have built over the past 3 years. Angel provides a fully integrated service offering, with the necessary manufacturing and regulatory experience to allow licensing of our products in the EU. As Materia Medica's established manufacturer for our antibody based products we look forward to working with Angel on future projects.

SP pulling back abit today but there should be more spikes coming along..there's lots of news coming along during 2011....so will stay in for time being!

same here, wasn't enough to cash in. but lookin good.,.

Good little write up in the Shares mag today (normally the kiss of death!)

Nothing new but said it was a buy on the back of all that's happening or...going to happen!

here's the share magazine article dated today.

ANGEL POISED TO SOAR

The likely purchase of a specialist facility to manufacture stem cells should help shares in angel biotechnology take flight. the 8.5m cap needs the extra capacity following growing demand from clients such as reneuron and Russian pharmaceutical company materia medica,with whom it announced a 1.5m contract win last month.

Shares says buy at. 40

thanks for that SH, earlier i sold and took the profit as before then back in at 33p so am very comfortable waiting for next surge, but seeing as RENE has 2 years i think trialing it seems a bit premature. Not complaining though well in profit so far.,.

Ticking up again this am, gives me 32% profit so far.,.

13% rise today lookin good.,. Up 40% so I suppose TFC would sell now??

up nearly 10% again this am.,.

don't forget this interim RNS 19/7/10... should get the trading update in the next week and... it can only get better ! (imho)

Gordon Sherriff, COO of Angel Biotechnology Holdings Plc, said:

"Angel has enjoyed a successful and productive first 6 months of 2010. In
addition to making our first ever half year profit, we have now secured most of
the business required to deliver our plan for 2010.
The business development team continue to secure new business for 2011,
currently amounting to almost 40% of our target and we expect to remain
profitable in H2 of 2010, to record the first annual profit in our history.
This is a remarkable achievement by the Company in a market that remains
challenging. This is a testament to the determined efforts of the business
development team to secure new business and the operational team to deliver our
clients milestones. The Directors are confident that the business has turned an
important corner and we expect to be able to build on this success.

We are actively assessing the options we have to increase our manufacturing
capacity and will update the market when our plans are complete."

Think this little company will bring home the bacon, might be slow but glad to be in.,.

Likely to get a trading update next Monday I reckon (imho)

don't want to add to the hype but it must be be a good time to buy more as these levels will not be seen again from a week or twos time (imho) there is so much news flow to come.

Surprised there's not many other ABH holders on this BB ?

Maybe that is because there is not much to say at this stage?! Very slow progress with this company but at least it is progress. They have a solid core business but as it is a Biotech company it is going to be looked at with justified trepidation until it has earned a 'must have this technology' tag. The indications are that the tag is becoming overdue, though it does appear that some of their customers have already figured that out! Angel are going to be around for a long time I think. I have been tempted to dump my relatively small holding on many occasions but there is just something that keeps me hanging on. The next update has to be encouraging, if not............???

I have traded these many times in the past and made money on them each time, but am ready to hold a bigger stake because i have a confidence in the company and the sp so far hasn't let us down. The tie up with RENE is good but will be a long haul, saying that, they have many other connections to keep them busy.

Yes, plenty to be getting on with; a few ups and downs for the sp in the meantime no doubt!

http://www.express.co.uk/money/view/225937/Small-companies-roundup-Angel-Biotech-up-on-deal-rumours

Very interesting this one.....could go ballistic on good news....really could...so snapped up a few....

Bought some more today......beginning to look good here.

this from daily express today

Angel Biotechnology eased 0.008p to 0.377p despite speculation it was close to securing a multi-million-pound manufacturing contract over several years with a Russian pharma company

Read more: http://www.express.co.uk/posts/view/226438/Small-companies-roundup-21st-Century-Technology-up-on-Sweden-dealSmall-companies-roundup-21st-Century-Technology-up-on-Sweden-deal#ixzz1CkDt4frZ

Great news can't wait to see it happen........ and the sp............watch this thread lol

Courtesy of the Voids news paper tips, mentioned twice.
Share Tips of the Week
Buy - RBS
Buy - Angel Biotechnology

Lets hope it all happens...and very soon too!

Shares Magazine

Risk-tolerant investors should look to buy Angel Biotechnology ahead of a maiden pre-tax profit announcement for the full year. In addition, the shares should receive a boost from news of further contract wins from pharmaceutical and biotech firms in need of access to Angel's innovative technology. Angel specialises in producing advanced biologics, such as stem cells and cellular vaccines, for clients under contract. House broker Matrix say: 'From 2012 we expect strong sustainable profitability for the business with excellent cash generation.' Buy.

this is forming a solid base to launch from...just need the good news releases to be issued soon and whooosh! we're away...(imho of course!)

The drop to low thirtys didn't last long, (long enough for me to buy) and has now steadied around forty just waiting to jump past 50 and on .... gl all.,.

Super rise...33%...wow...!...

Still 18% up....like wise wow.,.

Nice!

Are you ready for the rocket ride........here we go!!

More and more promising......

Fizz, fizz, fizzle, thfffptt. Oh, come on rocket, get a move on!!

ok maybe not but from 45 to 61 first thing, thought there might be a 70 + init....

Patience required BB. Or in ABH's case, patients, loads of them requiring stuff made by them! :o)

I'm starting to accumulate these......looks like a real performer....

my thoughts too.

Same here!

I meant to put this dinner time (put it on wrong thread) turns out so far i was right, but monday will tell:
copy: don't think it will drop like other times eg 30-40p reckon it might rest around 45-50 which is why i didn't sell this time.,.

30-40p If only;-)

abh is starting to impress - always been on my radar but with talk of further deals and a good 2012 predicted very interesting - only traded this so far - thinking of going long also

I've more than doubled my holding in these today, albeit at near the top.
2517

I Doubled too also not at bottom, couple of days ago.,.

on the move nicely up......keep going.....kerchinggg

Don't you just love sub penny shares when they're climbing......?....lovely....

At the moment anything that goes blue is lovely.,.

one of only a few gainers today.

ho ho ho!!! my 44p buy back into this on the 14.2.11 looks bl**dy good KKKKEEEEEEEEEEERRRRRRRRRRCHINGGGGGGGGGGGGGG

Well, well balerboy you are doing okay with this, great. My friend and I have been watching this since it was 0.26 - at that time nobody was recommending it, we did not buy so you are safe haha!! Many thanks for the back up this morning by the way. A little tale:- my cousins husband was a stock broker in the city for approx. 50 years - his head was that far up his own arse it wasn't true - he lost his own and my family thousands but died a millionaire plus. I, needless to say wasn't on his lucky list!!!!!!!!!!!!!!!

We are at the end of the day only trying to better ourselves and a little help goes a long long way. G & T time so good night and good luck tomorrow. Where did the unmentionable go today????????? it begins with an R and ends with an L

slightly down but no worry. been in lows and out 3 or 4 on the highs on this one but am now holding and building as there seems to be some substance to the company now.,. gl.... sorry you were not on the lucky list...like me it seems we got to make our own luck...lol

Up again.....at this rate ...it might have to be added to the golden list...XEL,RKH,GKP.....and it's not oil....

We could and should have a surge perhaps as far up as the 1p level on another contract announcement.....more sells than buys today but it makes no difference...it's rising....yummy.....

Very frustrating when buys show up as sells.....topped up and it shows as a sell ???...nuts....

we are out @ 0.62p with a very nice 20%+ profit.

Who's we ?....not amused ?...still in and hoping for much much more.....in fact double....

rf our profit is in the bank, where is yours?

Sold half ...you tempted me....like you say...best to bank some perhaps.....did not get as good a price as you but happy still the same, will keep the rest as this has a formidable future ahead....

don't panic and make your own decisions rf.

I'll keep the rest.....the trouble is that I have a large profit .....just had to take some...but will buy back if it turns out to be a mistake....

lol baler good to see you had a kerrrrrrrrrrrrrrrrchinnnnnnnnnnggggggggggggggg moment yesterday! lol :-))

i want to top up here tomorrow - if all goes well with jjb i will shove a large portion of that profit in here - abh has already and imo will continue to have a good 2011 with other contracts in the pipeline - assuming abh doesnt fly before i get a chance to that is - then i will have to wait for things to settle - jjb for me pure punt of a reasonable size - but rumour is that the outcome should be favourable - if not my top up here tomorrow will be smaller!! lol either way i will smile!

have a good evening all

3ms - i hope you are well - can you do me a favour - warn us if you are going to invest in abh! i'll abandon the abh ship quickly!! (i hope you have good sense of humour you seem to - didnt mean it of course!??!) - lol lol

have a good evening dudess

I am fine gibby thanks,

I may be naive but I am real, not according to someone on this bb. I haven't ventured into the abh ship yet, I should have done it months ago but I'll let you all know in good time if I even contimplate it. I am actually looking at something else which 'I will be good and not tell anyone' at least I made a few bob out of barclays, lloys and rbs when the going was good I had some common sense then. I wouldn't even in my naivety even go down those roads again (time being that is). Of course I have a sense of humour - I have to have as I got injured in my job so am limited as to what I can do so I enjoy doing this even if I do make a balls of things from time to time. Good night and here is to a better day tomorrow.

Your all safe for the mo.

Oh! gibby, I forgot to tell you that I have worked and dealt with men nearly all my life so what woman wouldn't need to have a sense of humour to survive that ooooooouuuuuuchhhhhhhh! Only joking at least I've survived!!!

lol 3ms - thanks for the offer of giving us the heads up should you come aboard the good ship abh!! bit worried about what else you may be looking into though lol!! i thought you had a good sense of humour, which is good of course - sorry to here you were injured - hope not too bad- and lol your last comment - have a good weekend and roll on next week

Results are encouraging.

Maiden pre-tax profit of 193,291(2009: loss of 753,730).

Revenue of 2.945 million (2009: 1.476 million, 100% increase).

Gross profit of 1.907 million (2009: 0.612 million, 212% increase).

Net assets value of 74,875.

I think a small kkeerrching needed!!

Try again. That's not big enough!!

time to buy a few more me thinks

it does look tempting, another contract must be due soon.,.

Good news on the way, especially now Astra zenica and the likes are having troubles as development will now pass to smaller comps, like ABH. time to top up with 3 new contracts signed.,.

Yep.. looking good

I'd almost forgotten that I'm still in this.....nice to see it perking up.....

Does seem a long time ago since we had the last rise.,.

rf-----like you I am still in ABH, but unlike you I have a constant reminder on my stockwatch list that I paid too much for them. Good news today though.
2517

Same here 2517, went back in to early at .44 will at some time buy somemore at 20 something to average down when time is right.,.

BB..have you bought more now we're at .20 ? I'm tempted... will continue to hold as there should be nothing but good news to come ! (imv)

quite agree, also tempted as another contract got to be coming soon.,.

All sells at the mo will be waiting for the tide to turn before investing here.,.

Looks like the buyers are back so have topped up, new contracts are a comin.,.

Another good contract win for angel, new labs.....bring it on.,.

Yes, this on the back of yesterday's Cardium deal is looking good.
2517

This one been hanging around for a bit now. Wonder if the new contract with rene will give it a boost.,.

It sure needs something to get it going (up)
2517

RNS another Aim stock bites the dust!

Sadly!
One suspects a little more than a smidgen of incompetence along the line, eh?

After moving to a new premises i expected better things from this comp, made plenty on them in the past but got caught out this time.,.

Have only a small holding left but still very annoyed that this company has got itself into this mess. The purchase of the collagen manufacturing facility in Glasgow last May was perhaps ill advised. Grrrr!